Dihydroergotamine (DHE) is typically administered by which routes for acute migraine management?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Dihydroergotamine (DHE) is typically administered by which routes for acute migraine management?

Dihydroergotamine must reach the systemic circulation in sufficient amount to stop an ongoing migraine, but it isn’t well absorbed when taken by mouth because of extensive first-pass metabolism in the liver. That makes oral dosing unreliable for rapid relief, which is why this medication isn’t used as a standard acute-treatment oral option. The intranasal route is used because absorption through the nasal mucosa bypasses much of the hepatic first-pass effect, providing a practical noninvasive way to achieve meaningful systemic exposure with a relatively quick onset. The intravenous route delivers the drug directly into the bloodstream, giving 100% bioavailability and the fastest, most predictable onset—crucial for severe or refractory attacks managed in the emergency department or hospital. Other routes like subcutaneous can be used in some settings but are not the typical first-line choices for acute management, and topical administration isn’t appropriate for systemic migraine treatment. So the best options for acute management are intranasal or intravenous administration, balancing noninvasive practicality with rapid, reliable relief.

Dihydroergotamine must reach the systemic circulation in sufficient amount to stop an ongoing migraine, but it isn’t well absorbed when taken by mouth because of extensive first-pass metabolism in the liver. That makes oral dosing unreliable for rapid relief, which is why this medication isn’t used as a standard acute-treatment oral option. The intranasal route is used because absorption through the nasal mucosa bypasses much of the hepatic first-pass effect, providing a practical noninvasive way to achieve meaningful systemic exposure with a relatively quick onset.

The intravenous route delivers the drug directly into the bloodstream, giving 100% bioavailability and the fastest, most predictable onset—crucial for severe or refractory attacks managed in the emergency department or hospital. Other routes like subcutaneous can be used in some settings but are not the typical first-line choices for acute management, and topical administration isn’t appropriate for systemic migraine treatment.

So the best options for acute management are intranasal or intravenous administration, balancing noninvasive practicality with rapid, reliable relief.

More practice questions